| Prostate Cancer |
1 |
1 |
| Toxicology |
0 |
0.9 |
| Prostate |
0 |
0.69 |
| Cancer |
0 |
0.56 |
| Metastasis |
0 |
0.43 |
| Prostate Specific Antigen |
0 |
0.43 |
| Radiation Therapy |
0 |
0.34 |
| Biologic Therapy |
0 |
0.32 |
| Bladder |
0 |
0.13 |
| Rectum |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.12 |
| Social Determinants of Health |
0 |
0.12 |
| Racial and Ethnic Disparity |
0 |
0.09 |
| Femoral |
0 |
0.06 |
| Health Care Services |
0 |
0.06 |
| Insurance |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| Salary and Compensation |
0 |
0.06 |
| Distant Metastasis |
0 |
0.04 |
| Radiation Proctitis |
0 |
0.04 |
| Accreditation |
0 |
0.03 |
| Adherence |
0 |
0.03 |
| Adverse Effects |
0 |
0.03 |
| Antigens |
0 |
0.03 |
| Board Certification |
0 |
0.03 |
| Cirrhosis |
0 |
0.03 |
| Clinical Guidelines |
0 |
0.03 |
| Cones |
0 |
0.03 |
| CT Scan |
0 |
0.03 |
| Hemorrhage |
0 |
0.03 |
| Hospital |
0 |
0.03 |
| Institutional Practice |
0 |
0.03 |
| Literacy |
0 |
0.03 |
| North Carolina |
0 |
0.03 |
| Office Visits |
0 |
0.03 |
| Patient Safety |
0 |
0.03 |
| Penis |
0 |
0.03 |
| Primary Care |
0 |
0.03 |
| Proctitis |
0 |
0.03 |
| Receptors |
0 |
0.03 |
| Seminal Vesicle |
0 |
0.03 |
| Socioeconomics |
0 |
0.03 |
| Testosterone |
0 |
0.03 |
| Biliary Disease |
0 |
0.02 |